Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients

• Published in: Clinical gastroenterology and hepatology Vol. 17; no. 3; pp. 568 - 570
• Main Authors: Simsek, Melek, Meijer, Berrie, Ramsoekh, Dewkoemar, Bouma, Gerd, van der Wouden, Egbert-Jan, den Hartog, Bert, de Vries, Annemarie C., Hoentjen, Frank, Dijkstra, Gerard, de Boer, Sybrand Y., Jansen, Jeroen M., van der Meulen, Andrea E., Beukers, Ruud, Brink, Menno A., Steinhauser, Toos, Oldenburg, Bas, Gilissen, Lennard P., Naber, Ton H., Verhagen, Marc A., de Boer, Nanne K.H., Mulder, Chris J.J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019
• Subjects: Adolescent; Adult; Aged; Azathioprine - administration & dosage; Azathioprine - adverse effects; Female; Humans; Hyperplasia - chemically induced; Hyperplasia - pathology; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - pathology; Liver Diseases - pathology; Male; Mercaptopurine - administration & dosage; Mercaptopurine - adverse effects; Middle Aged; Thioguanine - administration & dosage; Thioguanine - adverse effects; Young Adult
• ISSN: 1542-3565; 1542-7714
• DOI: 10.1016/j.cgh.2018.05.009

Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD).1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown.2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.